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kejby, Aalborg, and Odense, Denmark
bjectives This study sought to evaluate the platelet response to aspirin and the immature platelet
raction in patients with previous stent thrombosis (ST).
ackground ST is a potentially fatal complication of coronary stenting. A reduced platelet response
o aspirin increases the risk of cardiovascular events.
ethods We included 117 patients previously undergoing percutaneous coronary intervention. A
otal of 39 patients had suffered ST and 78 patients served as controls matched at a 1:2 ratio with
espect to age, sex, stent type, and percutaneous coronary intervention indication. All patients were
reated with aspirin 75 mg once daily. Platelet function was assessed by multiple electrode aggre-
ometry in citrated and hirudinized blood and by VerifyNow Aspirin Assay (Accumetrics, San Diego,
alifornia). Flow cytometric determination of the immature platelet fraction was performed to evalu-
te platelet turnover. Platelet activation was evaluated by soluble serum P-selectin. Compliance was
onﬁrmed by serum thromboxane B2.
esults All patients were fully compliant, which was conﬁrmed by suppressed levels of serum
hromboxane B2. Platelet aggregation was increased in patients with previous ST when assessed
y multiple electrode aggregometry induced by collagen (pcitrated blood  0.003; phirudinized blood
0.0001) and by arachidonic acid (pcitrated blood  0.16; phirudinized blood  0.04), respectively. Simi-
arly, platelet aggregation assessed by VerifyNow was higher in ST cases (p  0.12). A trend toward
n increased immature platelet fraction among cases was seen (p  0.13), whereas P-selectin levels
p  0.56) did not differ between groups.
onclusions Overall, patients with previous ST had a reduced antiplatelet effect of aspirin, which
ight be explained by an increased platelet turnover. (J Am Coll Cardiol Intv 2010;3:828–35)
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829tent thrombosis (ST) is a potentially fatal complication
ecessitating preventive dual antiplatelet therapy. Accord-
ngly, current guidelines recommend life-long treatment
ith aspirin and treatment with clopidogrel for 1 to 3 or 12
onths in patients with bare-metal stents (BMS) and
rug-eluting stents (DES), respectively (1). The risk of
efinite ST is approximately 0.6% within 15-month
ollow-up (2). By reducing neointimal hyperplasia, DES is
egarded more effective than BMS in reducing coronary
estenosis, but may pre-dispose patients to ST because
f incomplete endothelial coverage of the stent struts (3).
tent thrombosis might result from underexpansion or
alapposition of the stent, delayed re-endothelialization, or
oronary artery dissection. Other pre-disposing factors are
tent length, stent type, ST-segment elevation myocardial
nfarction, diabetes, renal failure, a reduced response to
lopidogrel, and premature discontinuation of antiplatelet
herapy (3,4).
Aspirin is the mainstay of secondary antithrombotic
herapy. Accordingly, low-dose aspirin reduces the risk of
ascular events by approximately 32% in high-risk patients
5). Although the antithrombotic properties of aspirin are
idely accepted, some patients have a lower platelet re-
ponse to aspirin. The risk of recurrent vascular events is 8%
o 18% within 2-year follow-up among patients on second-
ry preventive aspirin therapy. Two comprehensive meta-
nalyses (6,7) unequivocally state that a reduced platelet
esponse to aspirin carries a 4-fold risk of cardiovascular
vents. Previous studies have suggested that a reduced
esponse to aspirin predisposes specifically to ST (4,8).
The nature of a reduced aspirin response is multifac-
orial and might comprise clinical, biological, pharmaco-
ynamic, and genetic elements (9). A suggested biolog-
cal mechanism is based on a large fraction of immature
latelets caused by an increased platelet turnover (9 –13).
ontrary to mature platelets, newly formed platelets
xpress cyclooxygenase-2 (14) and contain ribonucleic
cid (RNA) enabling protein synthesis, which may influ-
nce their hemostatic potential.
The purpose of the present study was to evaluate the
latelet response to aspirin and the fraction of immature
latelets in patients with angiographically verified previ-
us ST compared with matched controls with no history
f ST.
ethods
esign. We performed a nested case-control study that
ncluded 117 patients previously undergoing percutaneous
oronary intervention (PCI). We included 39 patients
reviously diagnosed with ST, and 78 patients with no
istory of ST served as controls. Cases and controls were
atched at a 1:2 ratio with respect to the following riskactors for ST: age, sex, stent type, and indication for PCI. bPatients 18 years of age with angiographically verified
oronary artery disease were included in the study. All
atients underwent coronary stenting between January 1,
002, and June 30, 2005 (referred to as index PCI), and
ere treated with nonenteric-coated aspirin 75 mg once
aily prior to and during study participation.
Exclusion criteria were the following: aspirin intolerance,
ny acute or chronic disease (except for coronary artery
isease), use of anticoagulants or any drugs known to affect
latelet function (including clopidogrel and nonsteroidal
nti-inflammatory drugs), platelet count 120  109/l, any
schemic event or revascularization procedure (PCI or cor-
nary artery bypass grafting) within the previous 12 months,
nd inability to give informed consent.
Written informed consent was obtained from all partic-
pants. The study was conducted in accordance with the
elsinki II declaration, and the study protocol was
pproved by the Central Denmark Region Committees on
iomedical Research Ethics
project #2008-0189).
tudy population. Cases in our
tudy population originate from
study conducted by Kaltoft et
l. (2) that included 12,395 pa-
ients. The study evaluated mor-
ality and cardiovascular events
fter coronary stenting with ei-
her BMS or DES. A total of
18 patients with previous defi-
ite ST were identified accord-
ng to the Academic Research
onsortium criteria (15). Diag-
oses were adjudicated by a spe-
ialist committee on the basis of
edical records and coronary
ngiographies.
The recruitment of patients with previous ST is described
n detail in Figure 1. A total of 112 patients were alive when
he present study was initiated and 57 patients accepted the
nvitation to participate. Of these, 18 patients were excluded
ue to lifelong treatment with clopidogrel or vitamin K
ntagonists.
Control patients were identified in the Western Danish
eart Registry and enrolled according to pre-defined inclu-
ion and exclusion criteria. The Western Danish Heart
egistry collects data on all interventions performed in
nterventional centers in the western part of Denmark with
espect to patient and procedure characteristics.
aboratory measurements. Standardized blood sampling
as performed 1 h after aspirin ingestion. Patients were
esting for 30 min before sampling. Samples were drawn
rom an antecubital vein into vacuum tubes through a 19-G
Abbreviations
and Acronyms
ARU  aspirin reaction units
AU  aggregation units
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
IPF  immature platelet
fraction
MEA  multiple electrode
aggregometry
PCI  percutaneous
coronary intervention
RNA  ribonucleic acid
ST  stent thrombosis
S-TxB2  serum
thromboxane B2utterfly needle using a minimum of stasis.
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830Platelet aggregation was measured with multiple elec-
rode aggregometry (MEA) (Multiplate, Dynabyte, Mu-
ich, Germany) and with VerifyNow Aspirin Assay
Accumetrics Inc., San Diego, California). All platelet
ggregation analyses were performed within 2 h of sam-
ling. Blood was collected in 3.6-ml (for MEA) or 2.7-ml
erumo Venosafe (for VerifyNow) tubes containing 3.2%
odium citrate, and in 3-ml tubes (for MEA) containing
irudin 25 g/ml. Collagen (1.0 g/ml) and arachidonic
cid (1.0 mmol/l) served as MEA agonists. VerifyNow
nherently employs arachidonic acid as the agonist. The
EA results are expressed as area under the aggregation
urve (aggregation units [AU]·min) (16), whereas VerifyNow
esults are expressed as aspirin reaction units (ARU) (17).
Soluble serum P-selectin was determined by enzyme-
inked immunoadsorbent assay according to manufacturer’s
nstructions (R&D Systems, Minneapolis, Minnesota).
lood was collected in nonanticoagulated glass tubes and
llowed to clot at room temperature for 30 min before
entrifugation for 15 min at 1,000 g. The supernatant serum
as recovered and stored at –80°C.
The immature platelet fraction (IPF) was measured with
Sysmex XE-2100 hematology analyzer (Sysmex, Kobe,
Figure 1. Flow Chart of ST Patients
Flow chart showing the inclusion of patients with previous deﬁnite stent
thrombosis (ST).apan) with upgraded software (XE IPF Master, Sysmex) cllowing flow cytometric detection of the IPF as previously
escribed (13,18). Briefly, platelet RNA was stained with
uorescent dyes (polymethine and oxazine) before stained
ells were passed through a semiconductor diode laser beam
n the flow cytometer. The resulting fluorescence intensity
RNA content) and forward light scatter (cell volume) were
easured, and an algorithm integrated in the software discrim-
nated between mature and immature platelets. The IPF was
alculated as the ratio of immature platelets to the total platelet
ount and is given as a percentage.
Serum thromboxane B2 (S-TxB2) was determined ac-
ording to Patrono et al. (19), with the modification that
erum was collected after 1 h of clotting and that S-TxB2
as measured by enzyme-linked immunoadsorbent assay
Cayman Chemical, Ann Arbor, Michigan). Blood was
ollected in nonanticoagulated glass tubes and allowed to
lot at 37°C. Subsequently, it was centrifuged for 10 min at
,600 g and the supernatant serum was stored at –80°C.
ompliance. Compliance was evaluated by face-to-face in-
erviews and pill counting and confirmed by S-TxB2 mea-
urements. In order to optimize compliance, patients re-
eived a tablet dosage box containing 7 nonenteric-coated
spirin tablets and were instructed to save these for the last
days before blood sampling.
tatistics. Continuous data are presented as mean  SD if
ata were normally distributed, as geometric mean with 95%
onfidence interval if normally distributed when log-
ransformed, and as medians with interquartile range (IQR)
f not. Unpaired data were compared by the 2-sample t test
f normally distributed and by the Mann-Whitney U test if
ot. Distributions of categorical variables were compared
ith the chi-square test and presented as absolute counts
nd percentages. Aggregation measures in cases and con-
rols were compared by linear regression analysis adjusting
or the matched design by using robust standard errors
vce[cluster] option in Stata [StataCorp, College Station,
exas]), and further adjusting for smoking, treatment with
roton pump inhibitors, previous coronary artery bypass
rafting, and diabetes. A 2-tailed probability value of p 
.05 was considered statistically significant. Statistical anal-
ses were performed using GraphPad Prism version 5.0
GraphPad Software, La Jolla, California) and Stata version
0.0.
From previous studies we know that patients with coro-
ary artery disease on aspirin therapy display an average
ggregation of 430 ARU with a standard deviation of 30
ssessed by VerifyNow (17). A pre-defined minimal relevant
ifference was set at 18 ARU. According to a 2-sided alpha
evel of 5% and a statistical power of 90%, an estimated
ample size of 59 patients with previous ST was calculated.
e were able to include 39 patients with previous ST, but
ompensated by matching at a 1:2 ratio.
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831esults
aseline and procedure characteristics are shown in
ables 1 and 2, respectively. The groups were carefully
atched with respect to age, sex, stent type, and indication
or PCI. There was an excess of previous myocardial
nfarction and PCI in the case group, though explainable as
ll cases suffered an extra myocardial infarction and under-
ent an extra PCI as part of their event of ST. When
djusted for this extra event, the number of previous
yocardial infarction and previous PCI did not differ
etween groups.
A higher prevalence of previous coronary artery bypass
rafting was found in the case group, one of which was
erformed under the indication of ST. Furthermore, the use
f proton pump inhibitors was somewhat higher in the case
roup, whereas more smokers were included in the control
roup. The 2 groups also significantly differed with respect
Table 1. Baseline Characteristics of Study Population
Patients With ST
(n  39)
Control Patients
(n  78) p Value
Demographics
Age, yrs* 63.8 (11.3) 63.7 (11.1) NS
Male sex† 34 (87.1) 68 (87.1) NS
Risk factors
Smoking† 0.01
Never 26 (66.7) 29 (37.2)
At index procedure 7 (17.9) 24 (30.8)
Today 6 (15.4) 25 (32.1)
Family history of IHD† 24 (61.5) 51 (65.4) NS
Body mass index, kg/m2‡ 28.1 (26.7–29.5) 28.0 (27.3–28.8) NS
Diabetes† 5 (12.8) 13 (16.7) NS
Biochemistry
Creatinine, mol/l§ 80.0 (67.5–97.5) 79.0 (67.8–88.3) NS
Platelets, 109/l* 235.2 (47.8) 235.4 (47.8) NS
Medical history
Previous MI, n§ 2 (1–2) 1 (0–1) 0.0001
Previous PCI, n§ 2 (2–3) 1 (1–2) 0.0001
Previous CABG† 8 (20.5) 2 (2.6) 0.001
Previous stroke† 3 (7.7) 6 (7.7) NS
Medication
Statins† 38 (97.4) 72 (76.9) NS
Beta-blocker† 32 (82.1) 56 (71.8) NS
ACE inhibitor† 19 (48.7) 38 (48.7) NS
AT-II receptor antagonist† 5 (12.8) 18 (23.1) NS
Calcium antagonist† 7 (17.9) 19 (24.4) NS
Diuretics† 16 (41.0) 23 (29.5) NS
Proton pump inhibitor† 9 (23.1) 7 (9.0) 0.05
*Mean (SD), comparison made using t test. †n (%), comparison made using chi-square test.
‡Geometric mean (95% confidence interval), comparisonmade using t test. §Median (interquar-
tile range), comparison made using Mann-Whitney U test.
ACE angiotensin-converting enzyme; AT-II angiotensin-2; CABG coronary artery bypass
grafting; IHD ischemic heart disease; MImyocardial infarction; PCI percutaneous coronaryaintervention; ST stent thrombosis.o the vessel subjected to index PCI. Thus, aggregation
nalyses are adjusted for smoking, treatment with proton
ump inhibitors, number of previous coronary artery bypass
rafting, and diabetes.
Within the case population, 26 patients were on aspirin
nd clopidogrel at the time of ST, whereas the remaining 13
atients were on aspirin only. When explicitly asked before
lood sampling, all patients confirmed they had been
dherent to aspirin at the time of ST. The median time from
ndex PCI to onset of ST was 10 (range 0 to 1,030) days.
latelet aggregation. MEA. Analyses were completed in all
atients except for 1 case in whom hirudin glasses were
iscarded due to passed expiration date. As shown in Figure
, patients with previous ST had an increased platelet
ggregation irrespective of the type of agonist and antico-
gulant used. Whether induced by collagen (citrated blood:
edian 176 [IQR 117 to 255] vs. 116 [IQR 66 to 166]
U·min, p  0.003; hirudinized blood: 312 [IQR 218 to
96] vs. 185 [IQR 113 to 260] AU·min, p  0.0001) or by
Table 2. Onset of ST and Procedural Characteristics of Index PCI
Patients With ST
(n  39)
Control Patients
(n  78) p Value
Onset of ST*
Acute (24 h) 5 (12.8)
Early (1 to 30 days) 16 (41.0)
Late (30 days to 1 yr) 6 (15.4)
Very late (1 yr) 12 (30.8)
Stent type BMS* 22 (56) 44 (56) NS
Clinical presentation* NS
Stable AP 14 (35.9) 28 (35.9)
Non-STEMI/UAP 8 (20.5) 16 (20.5)
STEMI 17 (43.6) 34 (43.6)
Lesion length, mm† 17.3 (14.1–21.1) 14.7 (13.1–16.5) NS
Total stent length, mm† 21.3 (18.0–25.4) 17.8 (15.9–19.9) NS
Maximum balloon
diameter, mm†
3.4 (3.2–3.6) 3.4 (3.3–3.6) NS
Maximum balloon
pressure, atm†
14.0 (12.9–15.3) 14.2 (13.3–15.1) NS
Post-PCI MLD, mm† 3.3 (3.1–3.5) 3.3 (3.2–3.5) NS
Stenosis, % of luminal
diameter‡
97.0 (90–100) 97.5 (90–100) NS
Procedure time, min† 28.7 (23.1–35.5) 23.4 (20.4–26.8) NS
GP IIb/IIIa inhibitor* 20 (51.3) 46 (59.0) NS
Occluded artery* 0.05
RCA 12 (30.1) 26 (33.3)
LAD 24 (61.5) 32 (41.0)
LCX 3 (7.7) 20 (25.6)
*n (%), comparison made using chi-square test. †Geometric mean (95% confidence interval),
comparison made using t test. ‡Median (interquartile range), comparison made using Mann-
Whitney U test.
AP  angina pectoris; BMS  bare-metal stent(s); GP  glycoprotein; LAD  left anterior
descending coronary artery; LCX left circumflex artery;MLDminimum luminal diameter; RCA
 right coronary artery; STEMI  ST-segment elevation myocardial infarction; UAP  unstable
angina pectoris; other abbreviations as in Table 1.rachidonic acid (citrated blood: median 164 [IQR 102 to
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83246] vs. 129 [IQR 77 to 204] AU·min, p  0.16; hirudi-
ized blood: 230 [IQR 150 to 341] vs. 170 [IQR 78 to 301]
U·min, p  0.04), residual platelet aggregation was
igher in patients with previous ST. The difference was
ore pronounced, however, when aggregation was induced
y collagen. We observed a more potent inhibition of
latelet aggregation in citrated blood than in hirudinized
lood regardless of the agonist used (all p values 0.05).
ERIFYNOW. Analyses were completed in all patients except
or 2 (1 case and 1 control) in whom analyses were stopped
rematurely due to instrument error messages. As shown in
igure 3, platelet aggregation was higher in patients with
revious ST than in control patients (median 416 [IQR 404
o 434] ARU vs. 409 [IQR 400 to 422] ARU, p  0.12).
latelet activation. Soluble serum P-selectin levels did not
iffer between groups (mean 81.0  29.8 ng/ml vs. 82.3 
2.4 ng/ml, p  0.56).
latelet turnover. Platelet turnover was assessed by the IPF
s shown in Figure 4. Due to technical fallbacks, IPF mea-
urements were only performed in 103 (88%) patients. The
PF did not significantly differ between cases (n  25) and
ontrols (n  77) although a trend was seen (median: 2.7%
IQR 2.2% to 3.8%] vs. 2.3% [IQR 1.7% to 3.1%], p 0.13).
ompliance. All patients returned empty pill boxes and
Figure 2. Platelet Aggregation by MEA
Platelet aggregation in 117 patients with coronary artery disease: 39 patients w
thrombosis (controls). Aggregation was induced by collagen 1.0 g/ml in (A) c
(C) citrated and (D) hirudinized blood. AU  aggregation units; AUC  area ulaimed to be adherent to aspirin. In addition, all patientsemonstrated S-TxB2 levels (geometric mean: 1.53 (95%
onfidence interval: 0.67 to 2.86), range 0.139 to 18.18
g/ml) far below the normal range of 327  123 ng/ml in
ealthy individuals not on aspirin therapy (20) and well
revious stent thrombosis (cases) and 78 patients with no history of stent
d and (B) hirudinized blood as well as by arachidonic acid 1.0 mmol/l in
he aggregation curve; MEA  multiple electrode aggregometry.
Figure 3. Platelet Aggregation by VerifyNow
Platelet aggregation in 115 patients with coronary artery disease: 38
patients with previous stent thrombosis (cases) and 77 patients with noith p
itratehistory of stent thrombosis (controls). ARU  aspirin reaction units.
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833elow 30 ng/ml, corresponding to a more than 95% inhi-
ition of platelet cyclooxygenase-1 activity (21).
iscussion
e evaluated platelet aggregation in 117 patients previously
ubjected to coronary stenting and found an increased
latelet aggregation in patients previously suffering definite
T. This finding stresses the importance of platelet aggre-
ation in the pathophysiology of ST and may partly explain
he excess of cardiovascular events in patients suffering ST.
Our study is the largest to specifically investigate the
latelet response to aspirin in patients with angiographically
erified ST defined according to the Academic Research
onsortium criteria (15). Patients were fully compliant with
spirin monotherapy and were matched for 4 important ST
isk factors. Compared with our sample size calculation, we
ncluded a larger number of control patients to compensate
or the inclusion of less ST patients than expected (Fig. 1).
into Slottow et al. (22) evaluated the platelet response to
spirin by VerifyNow and, in agreement with our findings,
eported an increased platelet aggregation in 26 patients
ith previous ST compared with 21 control patients. All
hese patients were on dual antiplatelet therapy, though.
Previously, Gum et al. (23) have shown that a reduced
esponse to aspirin is a significant predictor of cardiovascular
vents in patients with coronary artery disease. Furthermore,
ori et al. (4) identified a reduced platelet response to
spirin and clopidogrel as an independent predictor of ST.
n accordance with Wenaweser et al. (8), we found arachi-
onic acid-induced platelet aggregation by MEA to be
igher in patients with previous ST than in matched
Figure 4. Immature Platelet Fraction
The immature platelet fraction (IPF) in patients with previous stent throm-
bosis and matched controls.ontrols. Similarly, in our study collagen-induced platelet pggregation by MEA was significantly higher in patients
ith ST.
The pathophysiology of ST partly depends on the timing
f the event. Acute (24 h) and early (1 day to 30 days) ST
ay result from elastic recoil and platelet-dependent mural
hrombus formation caused by periprocedural vessel injury
r stent underexpansion, whereas late (30 days to 1 year)
nd very late (1 year) ST are often caused by chronic
orphological changes as part of arterial remodeling (3). Of
he 39 ST patients in our study, 21 suffered acute or early
T, whereas the remaining 18 patients suffered late or very
ate ST. We acknowledge that such heterogeneity likely
overs different pathophysiological mechanisms, including
eriprocedural complications.
Overall, ST patients had a higher residual platelet aggre-
ation during treatment with aspirin. Additionally, a trend
oward an increased IPF was seen, although our study was
ot powered to detect such differences. The larger IPF
ndicates that an increased platelet turnover might be
mportant for platelet aggregation and the platelet response
o aspirin. Recently, a higher platelet aggregation in indi-
iduals with an increased platelet turnover has been dem-
nstrated in healthy individuals (10,11) and in patients with
cute coronary syndrome (12). Newly formed immature
latelets express cyclooxygenase-2 (14) and contain RNA
nabling protein synthesis, which may influence their he-
ostatic potential. Furthermore, the accelerated platelet
urnover per se may also be important. In patients with a
igh platelet turnover, platelets unaffected by aspirin are
ntroduced into the blood stream possibly causing the
verall platelet inhibition to be insufficient, especially during
he last hours of the dosing interval (24).
Previously, platelet aggregation in patients on dual anti-
latelet therapy has been evaluated (4,25), whereas platelet
ggregation in patients on aspirin monotherapy has only
een sparsely investigated. Firm conclusions on the bio-
hemical mechanisms underlying a reduced aspirin response
re difficult to draw from studies evaluating patients on dual
ntiplatelet therapy, because several interdependent platelet
ctivation pathways are simultaneously inhibited (26).
All patients in our study were treated with aspirin 75 mg
nce daily, ensuring a more than 95% inhibition of platelet
yclooxygenase-1 activity. No further increase in antiplatelet
otency is obtained by dose increments, whereas the rate of
leeding complications is likely to increase (5). It remains
ncertain whether a reduced platelet response to aspirin can
e overcome by dose increments; however, the results of the
ngoing CURRENT–OASIS 7 (Clopidogrel Optimal
oading Dose Usage to Reduce Recurrent Events–
rganization to Assess Strategies in Ischemic Syndromes)
rial (27) are expected to shed light on this field.
In clinical practice, a reduced platelet response to aspirin
s often attributable to noncompliance (28). In our study, all
atients were fully compliant according to S-TxB2, which is
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834egarded as the most specific test for measuring the effect of
spirin on platelets (29).
Platelet aggregation analyses by MEA were performed in
oth citrated and hirudinized blood, the latter of which
llowed us to investigate platelet function in a Ca2- and
g2-rich environment. Platelet aggregation was more
otently inhibited under citrate preservation regardless of
he agonist used, which might result from the acidification
nd the chelation of divalent cations caused by citrate.
The use of proton pump inhibitors was higher among
atients with previous ST (Table 1). Safety concerns have
risen from reports of a potential drug interaction between
lopidogrel and proton pump inhibitors (30,31). Recently,
e evaluated the antiplatelet effect of aspirin in patients with
oronary artery disease concomitantly treated with proton
ump inhibitors (32). This study suggested that proton
ump inhibitors reduce the antiplatelet effect of aspirin and,
ccordingly, in the present study, we adjusted for the use of
roton pump inhibitors.
Standardized and highly reproducible methods are
eeded before platelet function testing can be adopted into
linical practice. At present, an increasingly large number of
latelet function tests are available each employing a differ-
nt methodological approach. Abundant data suggest that
erifyNow (33,34) and MEA (16) are among the most
eliable methods for predicting cardiovascular events.
tudy limitations. The retrospective nature of our study did
ot allow the demonstration of any causality between ST
nd residual platelet aggregation during treatment with
spirin. Therefore, our findings should be considered
ypothesis-generating. Furthermore, a considerable number
f potentially eligible patients were treated with antithrom-
otic drugs other than aspirin, causing potential selection
ias. Accordingly, we were not able to include as many case
atients as estimated by the sample size calculation. We
cknowledge that the inclusion of both BMS and DES
ight result in several different pathophysiological mecha-
isms underlying our findings.
onclusions
n our study, patients with previous ST had a higher
esidual platelet aggregation during treatment with aspirin
han matched controls. This might be explained by an
ncreased platelet turnover. Point-of-care platelet function
esting might carry the potential to identify patients at
ncreased risk of ST. Clinical randomized studies are needed
o clarify whether optimizing antithrombotic therapy re-
uces the risk of cardiovascular events in high-risk patients.
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